Johannes Hartung

Johannes Hartung

Auto-generated profile, based on publicly available information

Johannes Hartung

Department of Cardiology, University Medicine Charité Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2026 in New England Journal of Medicine
Verified
Journal Article
Closed access
ULUlf Landmesser
Ulf Landmesser
CSCarsten Skurk
Carsten Skurk
PKPaulus Kirchhof
Paulus Kirchhof
TLThorsten Lewalter
Thorsten Lewalter
JHJohannes Hartung
Johannes Hartung
IEIngo Eitel
Ingo Eitel
Catheter-based closure of the left atrial appendage is an alternative to oral anticoagulation for stroke prevention in patients with atrial fibrillation. The effectiveness of this strategy, as compared with physician-directed best medical care, in patients at high risk for stroke and bleeding is unknown. In this multicenter randomized trial conducted in Germany, we assigned patients with atrial fibrillation and a high risk of stroke and bleeding to undergo left atrial appendage closure or to receive physician-directed best medical care (including direct oral anticoagulants, if eligible). The primary end point, tested for noninferiority, was a composite of stroke (ischemic or hemorrhagic), systemic embolism, major bleeding, or cardiovascular or unexplained death, assessed in a time-to-event analysis. The noninferiority margin was a hazard ratio of 1.3. A total of 912 adult patients underwent randomization. The primary end-point analysis included 446 patients who were assigned to undergo left atrial appendage closure (device group) and 442 who were assigned to physician-directed best medical care (medical-therapy group). The mean (±SD) age was 77.9±7.1 years; 38.6% of the patients were women, the mean CHA2DS2-VASc score was 5.2±1.5 (range, 0 to 9, with higher scores indicating a greater risk of stroke), and the mean HAS-BLED score was 3.0±0.9 (range, 0 to 9, with higher scores indicating higher risk of bleeding). After a median follow-up of 3 years (interquartile range, 1.7 to 4.7), a first primary end-point event had occurred in 155 patients (incidence per 100 patient-years, 16.8) in the device group and in 127 patients (incidence per 100 patient-years, 13.3) in the medical-therapy group (difference in restricted mean survival time, -0.36 years; 95% confidence interval, -0.70 to -0.01; P = 0.44 for noninferiority). Serious adverse events occurred in 368 patients (82.5%) in the device group and 342 (77.4%) in the medical-therapy group. Among patients with atrial fibrillation at high risk for stroke and bleeding, left atrial appendage closure was not noninferior to physician-directed best medical care with regard to a composite end point of stroke, systemic embolism, major bleeding, or cardiovascular or unexplained death. (Funded by the German Center for Cardiovascular Research; CLOSURE-AF ClinicalTrials.gov number, NCT03463317.).

16 January 2020 in JCI Insight
Verified
Journal Article
Closed access
PDF file
MCMathias Cardner
Mathias Cardner
MYMustafa Yalcinkaya
Mustafa Yalcinkaya
SGSandra Goetze
Sandra Goetze
ELEdlira Luca
Edlira Luca
MBMiroslav Balaz
Miroslav Balaz
Arnold Von EckardsteinArnold Von Eckardstein
Arnold Von Eckardstein
High-density lipoproteins (HDL) contain hundreds of lipid species and proteins and exert many potentially vasoprotective and antidiabetogenic activities on cells. To resolve structure-function-disease relationships of HDL, we characterized HDL of 51 healthy subjects and 98 patients with diabetes (T2DM), coronary heart disease (CHD), or both for protein and lipid composition, as well as functionality in 5 cell types. The integration of 40 clinical characteristics, 34 nuclear magnetic resonance (NMR) features, 182 proteins, 227 lipid species, and 12 functional read-outs by high-dimensional statistical modeling revealed, first, that CHD and T2DM are associated with different changes of HDL in size distribution, protein and lipid composition, and function. Second, different cellular functions of HDL are weakly correlated with each other and determined by different structural components. Cholesterol efflux capacity (CEC) was no proxy of other functions. Third, 3 potentially novel determinants of HDL function were identified and validated by the use of artificially reconstituted HDL, namely the sphingadienine-based sphingomyelin SM 42:3 and glycosylphosphatidylinositol-phospholipase D1 for the ability of HDL to inhibit starvation-induced apoptosis of human aortic endothelial cells and apolipoprotein F for the ability of HDL to promote maximal respiration of brown adipocytes.

5 December 2012 in Classical and Quantum Gravity
Verified
Journal Article
Open access
MTM Tessmer
M Tessmer
JHJ Hartung
J Hartung
GSG Schäfer
G Schäfer

4 February 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MRMarkus Reinthaler
Markus Reinthaler
JGJohannes Grosshauser
Johannes Grosshauser
TSTanja Schmidt
Tanja Schmidt
JUJuliane Unger
Juliane Unger
RMRoss Morgan
Ross Morgan
CSCarsten Skurk
Carsten Skurk
Left atrial appendage (LAA) closure is being developed as an alternative for stroke prevention in patients with atrial fibrillation that cannot tolerate long-term oral anticoagulation. To assess the feasibility, safety, and performance of a novel modified Occlutech LAA closure device in a preclinical porcine model, the modified Occlutech modified Occlutech Plus LAA closure device was implanted in 12 female pigs (25–39 kg body weight) under fluoroscopic and transesophageal echocardiography (TEE) guidance. Procedural and technical success, as well as safety of LAA closure, were evaluated peri-procedurally and after 4, 8, and 12 weeks. Moreover, after 4, 8 and, 12 weeks animals were sacrificed for pathological analysis (e.g., thrombus formation, device ingrowth, endothelialization, and inflammation). All LAA closure devices were successfully implanted. On follow-up, no serious adverse events such as device-associated thrombus or translocalization/embolization were observed. A clinically non-significant pericarditis was observed in 4 animals at the time of autopsy. Endothelialization of the device was visible after 4 weeks, advanced after 8 weeks and completed after 12 weeks. Immunohistochemistry showed low amounts of inflammatory infiltration on the edges of the device. The results of this study indicate that implantation of a modified Occlutech LAA closure device is feasible with rapid endothelialization and low inflammatory infiltration in a porcine model. Human data are needed to further characterize safety and efficacy.

3 November 2017 in Herzschrittmachertherapie + Elektrophysiologie
Verified
Journal Article
Closed access
PDF file
CSCarsten Skurk
Carsten Skurk
JHJohannes Jakob Hartung
Johannes Jakob Hartung
ULUlf Landmesser
Ulf Landmesser

4 September 2018 in Die Innere Medizin
Verified
Journal Article
Closed access
PDF file
CSC. Skurk
C. Skurk
JHJ. J. Hartung
J. J. Hartung
DLD. M. Leistner
D. M. Leistner
ULU. Landmesser
U. Landmesser